Thivyah Prabha, Rasheed Khan, Shruthi Cn, Rathi Priya,
Volume 17, Issue 6 (Nov-Dec 2023)
Abstract
Background: Thyroid disorders are the most common cause of endocrine dysfunction among women of childbearing age. It is well-established that hypothyroid dysfunction can have significant adverse effects on pregnancy and fetal development. This study aimed to determine the prevalence of thyroid disorders among antenatal women and assess the maternal and fetal outcomes in pregnant women with hypothyroid disorders.
Methods: This prospective study was conducted in the antenatal clinic of the Department of Obstetrics and Gynaecology in association with the Biochemistry Department. After obtaining written informed consent, antenatal women aged 18-40 years were included in this study, regardless of their gestational period. Venous blood samples were collected from the antecubital vein, and thyrotropin, free triiodothyronine (free T3), and free thyroxine (free T4) levels were measured. Hypothyroid antenatal women were monitored throughout their pregnancies to evaluate maternal and fetal outcomes.
Results: Among the participants in this study, 149 antenatal women had thyroid disorders, with a prevalence rate of 12.6%. Subclinical hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, and overt hyperthyroidism were observed in 6.9%, 3.2%, 1.8%, and 0.7% of cases, respectively. Maternal complications included oligohydramnios (5.8%), preeclampsia (13.3%), and preterm delivery (5%), while fetal complications included low birth weight (20.8%), hyperbilirubinemia (9.1%), and neonatal intensive care unit (NICU) admissions (13.3%).
Conclusion: A high prevalence (12.6%) of thyroid disorders, particularly hypothyroidism (10.1%), among pregnant women, emphasizing the importance of routine thyroid testing for all antenatal individuals.
Bizav Rasheed , Beri Tawfeq,
Volume 18, Issue 6 (Nov-Dec 2024)
Abstract
Background: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. This study aimed to evaluate the effect of methotrexate on blood, liver, and renal parameters in patients with RA.
Methods: A six-month cross-sectional study was carried out on 60 consecutive patients aged 19-70 years diagnosed with RA on methotrexate treatment (10 mg) orally per week. A questionnaire was taken from participants, and laboratory tests were done on renal and liver function and complete blood count (CBC), erythrocyte sedimentation rate (ESR), glutamic oxaloacetic transaminase (SGOT or AST), glutamate pyruvate transaminase (SGPT or ALT), Creatinine, C-reactive protein (CRP), and rheumatoid factor (RF) as a follow-up to drug intake.
Results: At the end of sample collection, participants ranged in age from 19 to 70 years, with a female-to-male ratio of 1.5:1. Significant differences in platelet (PLT) levels were observed only between days 1 and 14 of the treatment (p <0.05). Similarly, SGPT levels showed significant variation between days 1 and 30 of the treatment (p <0.05). Additionally, RF levels exhibited significant differences between days 1 and 14 (p <0.01) and between days 1 and 30 of the treatment (p <0.04).
Conclusion: The recommended medication for all kinds of patients with RA is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics can serve as indicators for monitoring the medication’s effectiveness, safety, and patient follow-up.
